Bevacizumab potentiates chemotherapeutic effect on t-leukemia/lymphoma cells by direct action on tumor endothelial cells

Haematologica

Volumn 96, Issue 6, 2011, Pages 927-931

  Wang, Li ^a,b   Shi, Wen Yu ^a   Yang, Fan ^a,b   Tang, Wei ^a   Gapihan, Guillaume ^b,c,d,e   Varna, Mariana ^b,c,d,e   Shen, Zhi Xiang ^a   Chen, Sai Juan ^a,b   Leboeuf, Christophe ^b,c,d,e   Janin, Anne ^b,c,d,e   Zhao, Wei Li ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Pole de Recherches Franco Chinois en Science du Vivant et Genomique   (China)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

And endothelial cells; Bevacizumab; T cell leukemia lymphoma

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL OCCLUSION; CANCER INHIBITION; CELL INTERACTION; CELL SWELLING; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; LEUKEMIA CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; T CELL LEUKEMIA; TUMOR CELL; TUMOR ENDOTHELIAL CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; JURKAT CELLS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958040093     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.037689     Document Type: Article

References (23)

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-26.
2. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23(5): 949-71, v.
3. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia. 2010;24(1):13-21.
4. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.
5. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6(9):507-18.
6. Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. Clin Cancer Res. 2006;12(23):6978-84.
7. Paydas S, Ergin M, Erdogan S, Seydaoglu G. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res. 2008;32(9):1424-30.
8. Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84(11):1512-9.
9. Tei K, Kawakami-Kimura N, Taguchi O, Kumamoto K, Higashiyama S, Taniguchi N, et al. Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. Cancer Res. 2002;62(21):6289-96.
10. Millan J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and Factin-rich domains. Nat Cell Biol. 2006;8(2): 113-23.
11. Boyd AW, Dunn SM, Fecondo JV, Culvenor JG, Duhrsen U, Burns GF, et al. Regulation of expression of a human intercellular adhesion molecule (ICAM-1) during lymphohematopoietic differentiation. Blood. 1989;73(7):1896-903.
12. Brooks KJ, Coleman EJ, Vitetta ES. The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. Int J Cancer. 2008;123(10):2438-45.
13. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabino -furanosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10(11): 3577-85.
14. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol. 2008;19(2):396-7.
15. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15(10):3495-502.
16. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13(2):120-5.
17. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727-39.
18. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671-80.
19. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895-904.
20. Haddad O, Chotard-Ghodsnia R, Verdier C, Duperray A. Tumor cell/endothelial cell tight contact upregulates endothelial adhesion molecule expression mediated by NFkappaB: differential role of the shear stress. Exp Cell Res. 2010;316(4):615-26.
21. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, et al. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer. 2008;123(9):2031-40.
22. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, et al. Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics. 2009; 19(3):181-92.
23. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.Circ Res. 2010;107(3):408-17.